PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant/refractory disease and frequent prior ...
TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
The safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy. Median number of prior lines of systemic therapy was three (range: 1-10) The ...
TP53 alterations independently predicted inferior remission, EFS, and OS after CAR T-cell therapy in relapsed/refractory B-ALL.
Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results